Targeting the AMPK pathway for the treatment of Type 2 diabetes. - Archive ouverte HAL Access content directly
Journal Articles Frontiers in bioscience : a journal and virtual library Year : 2009

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

(1) , (1) , (1) , (1) , (2) , (1) , (1) , (1, 2)
1
2
Benoît Viollet
Connectez-vous pour contacter l'auteur
Louise Lantier
Sophie Hébrard
  • Function : Author
Rémi Mounier
Marc Foretz

Abstract

Type 2 diabetes is one of the fastest growing public health problems worldwide, resulting from both genetic factors and inadequate adaptation to environmental changes. It is characterized by abnormal glucose and lipid metabolism due in part to resistance to the actions of insulin in skeletal muscle, liver and fat. AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase, acts as an integrator of regulatory signals monitoring systemic and cellular energy status. The growing realization that AMPK regulates the coordination of anabolic and catabolic metabolic processes represents an attractive concept for type 2 diabetes therapy. Recent findings showing that pharmacological activation of AMPK improves blood glucose homeostasis, lipid profile and blood pressure in insulin-resistant rodents suggest that this kinase could be a novel therapeutic target in the treatment of type 2 diabetes. Consistent with these results, physical exercise and major classes of antidiabetic drugs have recently been reported to activate AMPK. In the present review, we update these topics and discuss the concept of targeting the AMPK pathway for the treatment of type 2 diabetes.
Fichier principal
Vignette du fichier
Figures_3_4_correct.pdf (1.02 Mo) Télécharger le fichier
Vignette du fichier
AMPK_diabetes_FBS.pdf (661.35 Ko) Télécharger le fichier
Vignette du fichier
inserm-00367501_edited.pdf (508.94 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)

Dates and versions

inserm-00367501 , version 1 (11-03-2009)

Identifiers

  • HAL Id : inserm-00367501 , version 1
  • PUBMED : 19273282

Cite

Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al.. Targeting the AMPK pathway for the treatment of Type 2 diabetes.. Frontiers in bioscience : a journal and virtual library, 2009, 14, pp.3380-400. ⟨inserm-00367501⟩
168 View
1475 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More